FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220912097> ?p ?o ?g. }

• W4220912097 endingPage "e42" @default.
• W4220912097 startingPage "e42" @default.
• W4220912097 abstract "Purpose/Objective(s) In July 2019, the FDA approved pembrolizumab in combination with platinum and fluorouracil (P+C), or as monotherapy [P, in combined positive score (CPS) ≥1 population], for the first-line (1L) treatment of patients with R/M HNSCC based on KEYNOTE-048 trial results. Limited evidence exists on the real-world use of pembrolizumab therapy post-approval. The objective of this study was to assess demographic and clinical characteristics, and treatment patterns among patients initiating pembrolizumab therapy in 1L R/M HNSCC. Materials/Methods A retrospective cohort study was conducted using the Flatiron Health Advanced Head and Neck database. The study cohort included adult R/M HNSCC patients, who initiated 1L P or P+C between 07/01/2019 - 12/31/2020. Patients were excluded if they received prior platinum treatment ≤6 months of 1L pembrolizumab therapy, had other primary cancers before R/M HNSCC diagnosis, or were treated with a clinical study drug. Real-world time on treatment (rwToT) was assessed using Kaplan-Meier methods. Results A total of 402 patients initiated 1L pembrolizumab therapy, [P (n=264), P+C (n=138)]. Descriptive analyses showed differences between patients receiving P versus P+C (Table 1). Patients receiving P were older, and more likely to have a history of smoking, being HPV positive, and have higher ECOG score at 1L initiation. Other patient characteristics were similar between P versus P+C. Treatment pattern results showed that 68.2% (P: 72.0%, P+C: 60.9%) of pembrolizumab treated patients had a record of PD-L1 test before or within 30 days of 1L initiation in the data. Majority of these PD-L1 tests assessed CPS scores (71.8%) with 82.2% of patients CPS≥1 (P 85.8%, P+C 73.2%). The median 1L rwToT was 3.9 months (IQR: 1.4-8.5) for P and 4.9 months (IQR: 1.6−10.4) for P+C, consistent with the results of the KEYNOTE-048 trial [P: 3.5 months (IQR: 1.4-7.6), P+C: 5.8 months (IQR: 2.8-9.7)]. Conclusion In our real-world study, some patient differences regarding patient characteristics were observed between patients initiating P vs. P+C. Furthermore, 1L use of pembrolizumab was observed in a severe R/M HNSCC population (ECOG ≥ 2). rwTOT with P and P+C were consistent with results of the KEYNOTE-048 trial, thus validating trial results. Table 1. Baseline characteristics of patients initiating 1L P versus P+C In July 2019, the FDA approved pembrolizumab in combination with platinum and fluorouracil (P+C), or as monotherapy [P, in combined positive score (CPS) ≥1 population], for the first-line (1L) treatment of patients with R/M HNSCC based on KEYNOTE-048 trial results. Limited evidence exists on the real-world use of pembrolizumab therapy post-approval. The objective of this study was to assess demographic and clinical characteristics, and treatment patterns among patients initiating pembrolizumab therapy in 1L R/M HNSCC. A retrospective cohort study was conducted using the Flatiron Health Advanced Head and Neck database. The study cohort included adult R/M HNSCC patients, who initiated 1L P or P+C between 07/01/2019 - 12/31/2020. Patients were excluded if they received prior platinum treatment ≤6 months of 1L pembrolizumab therapy, had other primary cancers before R/M HNSCC diagnosis, or were treated with a clinical study drug. Real-world time on treatment (rwToT) was assessed using Kaplan-Meier methods. A total of 402 patients initiated 1L pembrolizumab therapy, [P (n=264), P+C (n=138)]. Descriptive analyses showed differences between patients receiving P versus P+C (Table 1). Patients receiving P were older, and more likely to have a history of smoking, being HPV positive, and have higher ECOG score at 1L initiation. Other patient characteristics were similar between P versus P+C. Treatment pattern results showed that 68.2% (P: 72.0%, P+C: 60.9%) of pembrolizumab treated patients had a record of PD-L1 test before or within 30 days of 1L initiation in the data. Majority of these PD-L1 tests assessed CPS scores (71.8%) with 82.2% of patients CPS≥1 (P 85.8%, P+C 73.2%). The median 1L rwToT was 3.9 months (IQR: 1.4-8.5) for P and 4.9 months (IQR: 1.6−10.4) for P+C, consistent with the results of the KEYNOTE-048 trial [P: 3.5 months (IQR: 1.4-7.6), P+C: 5.8 months (IQR: 2.8-9.7)]. In our real-world study, some patient differences regarding patient characteristics were observed between patients initiating P vs. P+C. Furthermore, 1L use of pembrolizumab was observed in a severe R/M HNSCC population (ECOG ≥ 2). rwTOT with P and P+C were consistent with results of the KEYNOTE-048 trial, thus validating trial results. Table 1. Baseline characteristics of patients initiating 1L P versus P+C" @default.
• W4220912097 created "2022-04-03" @default.
• W4220912097 creator A5017265970 @default.
• W4220912097 creator A5021395991 @default.
• W4220912097 creator A5030089146 @default.
• W4220912097 creator A5052244123 @default.
• W4220912097 date "2022-04-01" @default.
• W4220912097 modified "2023-09-27" @default.
• W4220912097 title "Real-World Patient Characteristics and Time on Treatment Outcomes Among Patients Receiving First-Line Pembrolizumab in the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the United States" @default.
• W4220912097 doi "https://doi.org/10.1016/j.ijrobp.2021.12.098" @default.
• W4220912097 hasPublicationYear "2022" @default.
• W4220912097 type Work @default.
• W4220912097 citedByCount "0" @default.
• W4220912097 crossrefType "journal-article" @default.
• W4220912097 hasAuthorship W4220912097A5017265970 @default.
• W4220912097 hasAuthorship W4220912097A5021395991 @default.
• W4220912097 hasAuthorship W4220912097A5030089146 @default.
• W4220912097 hasAuthorship W4220912097A5052244123 @default.
• W4220912097 hasConcept C121608353 @default.
• W4220912097 hasConcept C126322002 @default.
• W4220912097 hasConcept C143998085 @default.
• W4220912097 hasConcept C167135981 @default.
• W4220912097 hasConcept C2776530083 @default.
• W4220912097 hasConcept C2776833033 @default.
• W4220912097 hasConcept C2777701055 @default.
• W4220912097 hasConcept C2780057760 @default.
• W4220912097 hasConcept C2908647359 @default.
• W4220912097 hasConcept C71924100 @default.
• W4220912097 hasConcept C72563966 @default.
• W4220912097 hasConcept C99454951 @default.
• W4220912097 hasConceptScore W4220912097C121608353 @default.
• W4220912097 hasConceptScore W4220912097C126322002 @default.
• W4220912097 hasConceptScore W4220912097C143998085 @default.
• W4220912097 hasConceptScore W4220912097C167135981 @default.
• W4220912097 hasConceptScore W4220912097C2776530083 @default.
• W4220912097 hasConceptScore W4220912097C2776833033 @default.
• W4220912097 hasConceptScore W4220912097C2777701055 @default.
• W4220912097 hasConceptScore W4220912097C2780057760 @default.
• W4220912097 hasConceptScore W4220912097C2908647359 @default.
• W4220912097 hasConceptScore W4220912097C71924100 @default.
• W4220912097 hasConceptScore W4220912097C72563966 @default.
• W4220912097 hasConceptScore W4220912097C99454951 @default.
• W4220912097 hasIssue "5" @default.
• W4220912097 hasLocation W42209120971 @default.
• W4220912097 hasOpenAccess W4220912097 @default.
• W4220912097 hasPrimaryLocation W42209120971 @default.
• W4220912097 hasRelatedWork W2020823099 @default.
• W4220912097 hasRelatedWork W2963491961 @default.
• W4220912097 hasRelatedWork W2980510993 @default.
• W4220912097 hasRelatedWork W3000701650 @default.
• W4220912097 hasRelatedWork W3090002302 @default.
• W4220912097 hasRelatedWork W3103265772 @default.
• W4220912097 hasRelatedWork W3154194420 @default.
• W4220912097 hasRelatedWork W3154280247 @default.
• W4220912097 hasRelatedWork W3210496311 @default.
• W4220912097 hasRelatedWork W4323657820 @default.
• W4220912097 hasVolume "112" @default.
• W4220912097 isParatext "false" @default.
• W4220912097 isRetracted "false" @default.
• W4220912097 workType "article" @default.